EXACT SCIENCES CORP (EXAS) Fundamental Analysis & Valuation

NASDAQ:EXAS • US30063P1057

Current stock price

104.91 USD
+0.99 (+0.95%)
At close:
104.947 USD
+0.04 (+0.04%)
After Hours:

This EXAS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. EXAS Profitability Analysis

1.1 Basic Checks

  • EXAS had negative earnings in the past year.
  • EXAS had a positive operating cash flow in the past year.
  • In the past 5 years EXAS always reported negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: EXAS reported negative operating cash flow in multiple years.
EXAS Yearly Net Income VS EBIT VS OCF VS FCFEXAS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500M -1B

1.2 Ratios

  • Looking at the Return On Assets, with a value of -3.55%, EXAS belongs to the top of the industry, outperforming 86.13% of the companies in the same industry.
  • EXAS has a better Return On Equity (-8.66%) than 87.28% of its industry peers.
Industry RankSector Rank
ROA -3.55%
ROE -8.66%
ROIC N/A
ROA(3y)-8.02%
ROA(5y)-8.6%
ROE(3y)-19.33%
ROE(5y)-19.21%
ROIC(3y)N/A
ROIC(5y)N/A
EXAS Yearly ROA, ROE, ROICEXAS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10 -20 -30 -40

1.3 Margins

  • EXAS's Gross Margin of 69.69% is fine compared to the rest of the industry. EXAS outperforms 79.96% of its industry peers.
  • EXAS's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for EXAS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.28%
GM growth 5Y-1.78%
EXAS Yearly Profit, Operating, Gross MarginsEXAS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. EXAS Health Analysis

2.1 Basic Checks

  • EXAS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for EXAS has been increased compared to 1 year ago.
  • EXAS has more shares outstanding than it did 5 years ago.
  • EXAS has a better debt/assets ratio than last year.
EXAS Yearly Shares OutstandingEXAS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
EXAS Yearly Total Debt VS Total AssetsEXAS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

  • An Altman-Z score of 2.98 indicates that EXAS is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • The Altman-Z score of EXAS (2.98) is better than 68.59% of its industry peers.
  • EXAS has a debt to FCF ratio of 8.30. This is a slightly negative value and a sign of low solvency as EXAS would need 8.30 years to pay back of all of its debts.
  • EXAS's Debt to FCF ratio of 8.30 is amongst the best of the industry. EXAS outperforms 90.37% of its industry peers.
  • A Debt/Equity ratio of 0.97 indicates that EXAS is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.97, EXAS is not doing good in the industry: 74.76% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.97
Debt/FCF 8.3
Altman-Z 2.98
ROIC/WACCN/A
WACC8.87%
EXAS Yearly LT Debt VS Equity VS FCFEXAS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 2.43 indicates that EXAS has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.43, EXAS is doing worse than 71.29% of the companies in the same industry.
  • EXAS has a Quick Ratio of 2.17. This indicates that EXAS is financially healthy and has no problem in meeting its short term obligations.
  • EXAS has a worse Quick ratio (2.17) than 72.45% of its industry peers.
Industry RankSector Rank
Current Ratio 2.43
Quick Ratio 2.17
EXAS Yearly Current Assets VS Current LiabilitesEXAS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. EXAS Growth Analysis

3.1 Past

  • EXAS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 81.51%, which is quite impressive.
  • Looking at the last year, EXAS shows a quite strong growth in Revenue. The Revenue has grown by 17.69% in the last year.
  • The Revenue has been growing by 16.84% on average over the past years. This is quite good.
EPS 1Y (TTM)81.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.86%
Revenue 1Y (TTM)17.69%
Revenue growth 3Y15.92%
Revenue growth 5Y16.84%
Sales Q2Q%23.12%

3.2 Future

  • The Earnings Per Share is expected to grow by 41.90% on average over the next years. This is a very strong growth
  • EXAS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.67% yearly.
EPS Next Y129.51%
EPS Next 2Y79.15%
EPS Next 3Y56.78%
EPS Next 5Y41.9%
Revenue Next Year13.66%
Revenue Next 2Y13.01%
Revenue Next 3Y11.28%
Revenue Next 5Y9.67%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
EXAS Yearly Revenue VS EstimatesEXAS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B 5B
EXAS Yearly EPS VS EstimatesEXAS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4

More info and screens

Find the best growth stocksShow best growing peers

4

4. EXAS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for EXAS. In the last year negative earnings were reported.
  • EXAS is valuated quite expensively with a Price/Forward Earnings ratio of 345.14.
  • Based on the Price/Forward Earnings ratio, EXAS is valued cheaply inside the industry as 87.86% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 22.29. EXAS is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 345.14
EXAS Price Earnings VS Forward Price EarningsEXAS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 -100 200 300

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, EXAS is valued cheaper than 88.82% of the companies in the same industry.
  • EXAS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. EXAS is cheaper than 91.52% of the companies in the same industry.
Industry RankSector Rank
P/FCF 71.07
EV/EBITDA 951.56
EXAS Per share dataEXAS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • A more expensive valuation may be justified as EXAS's earnings are expected to grow with 56.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y79.15%
EPS Next 3Y56.78%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EXAS Dividend Analysis

5.1 Amount

  • EXAS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EXAS Fundamentals: All Metrics, Ratios and Statistics

EXACT SCIENCES CORP

NASDAQ:EXAS (3/20/2026, 8:00:01 PM)

After market: 104.947 +0.04 (+0.04%)

104.91

+0.99 (+0.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13
Earnings (Next)04-29
Inst Owners85.65%
Inst Owner Change-1.95%
Ins Owners1.2%
Ins Owner Change-120.77%
Market Cap20.03B
Revenue(TTM)3.25B
Net Income(TTM)-207.95M
Analysts66.9
Price Target104.35 (-0.53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-251.2%
Min EPS beat(2)-462.34%
Max EPS beat(2)-40.06%
EPS beat(4)1
Avg EPS beat(4)-111.73%
Min EPS beat(4)-462.34%
Max EPS beat(4)94.53%
EPS beat(8)3
Avg EPS beat(8)-223.98%
EPS beat(12)7
Avg EPS beat(12)-132.56%
EPS beat(16)11
Avg EPS beat(16)-95.01%
Revenue beat(2)2
Avg Revenue beat(2)1.49%
Min Revenue beat(2)0.03%
Max Revenue beat(2)2.95%
Revenue beat(4)4
Avg Revenue beat(4)1.56%
Min Revenue beat(4)0.03%
Max Revenue beat(4)2.95%
Revenue beat(8)4
Avg Revenue beat(8)0.22%
Revenue beat(12)6
Avg Revenue beat(12)0.94%
Revenue beat(16)10
Avg Revenue beat(16)1.37%
PT rev (1m)-1.08%
PT rev (3m)3.68%
EPS NQ rev (1m)21.62%
EPS NQ rev (3m)23.68%
EPS NY rev (1m)-9.15%
EPS NY rev (3m)-6.55%
Revenue NQ rev (1m)0.75%
Revenue NQ rev (3m)1.07%
Revenue NY rev (1m)0.11%
Revenue NY rev (3m)0.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 345.14
P/S 6.17
P/FCF 71.07
P/OCF 40.75
P/B 8.34
P/tB N/A
EV/EBITDA 951.56
EPS(TTM)-1.03
EYN/A
EPS(NY)0.3
Fwd EY0.29%
FCF(TTM)1.48
FCFY1.41%
OCF(TTM)2.57
OCFY2.45%
SpS17.01
BVpS12.58
TBVpS-4.65
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -3.55%
ROE -8.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.69%
FCFM 8.68%
ROA(3y)-8.02%
ROA(5y)-8.6%
ROE(3y)-19.33%
ROE(5y)-19.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.28%
GM growth 5Y-1.78%
F-Score6
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0.97
Debt/FCF 8.3
Debt/EBITDA 103.8
Cap/Depr 94.62%
Cap/Sales 6.46%
Interest Coverage N/A
Cash Conversion 2186.01%
Profit Quality N/A
Current Ratio 2.43
Quick Ratio 2.17
Altman-Z 2.98
F-Score6
WACC8.87%
ROIC/WACCN/A
Cap/Depr(3y)79.74%
Cap/Depr(5y)91.05%
Cap/Sales(3y)6%
Cap/Sales(5y)7.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.86%
EPS Next Y129.51%
EPS Next 2Y79.15%
EPS Next 3Y56.78%
EPS Next 5Y41.9%
Revenue 1Y (TTM)17.69%
Revenue growth 3Y15.92%
Revenue growth 5Y16.84%
Sales Q2Q%23.12%
Revenue Next Year13.66%
Revenue Next 2Y13.01%
Revenue Next 3Y11.28%
Revenue Next 5Y9.67%
EBIT growth 1Y-11.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year638.68%
EBIT Next 3Y123.48%
EBIT Next 5Y72.07%
FCF growth 1Y853.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y133.42%
OCF growth 3YN/A
OCF growth 5Y29.2%

EXACT SCIENCES CORP / EXAS Fundamental Analysis FAQ

What is the fundamental rating for EXAS stock?

ChartMill assigns a fundamental rating of 4 / 10 to EXAS.


What is the valuation status of EXACT SCIENCES CORP (EXAS) stock?

ChartMill assigns a valuation rating of 4 / 10 to EXACT SCIENCES CORP (EXAS). This can be considered as Fairly Valued.


Can you provide the profitability details for EXACT SCIENCES CORP?

EXACT SCIENCES CORP (EXAS) has a profitability rating of 3 / 10.


What is the financial health of EXACT SCIENCES CORP (EXAS) stock?

The financial health rating of EXACT SCIENCES CORP (EXAS) is 5 / 10.